Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,579.65
(
1.12%
)
US TECH 100
23,485.60
(
0.87%
)
Dow Jones
46,196.42
(
1.36%
)
Brent Oil
98.23
(
-9.16%
)
Bitcoin
70,602.80
(
4.08%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pcrutch post# 126244

Wednesday, 09/07/2011 10:40:03 AM

Wednesday, September 07, 2011 10:40:03 AM

Post# of 257269
HSP’s Epogen project has modest commercial upside at best, IMO. The US market for Epogen biosimilars will probably end up looking like the one in Europe, where there are many branded products each generating a tiny market share.

I don’t think HSP will be a player at all in substitutable biogenerics.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today